Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
live quadruple lactobacillus vaginal capsule
- Development stage
- Unknown
- Lead developer
- Shuangqi Pharmaceutical
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Vaginal
01
Overview
Live quadruple lactobacillus vaginal capsule is a live biotherapeutic product (LBP) containing four specific strains of beneficial bacteria: *Lactobacillus acidophilus*, *Lactobacillus casei*, *Lactobacillus rhamnosus*, and *Lactobacillus bulgaricus*. Developed and manufactured by Inner Mongolia Shuangqi Pharmaceutical, it is primarily indicated for the treatment of bacterial vaginosis and the restoration of vaginal microecology. The mechanism involves the colonization of the vaginal epithelium by these lactobacilli, which produce lactic acid and hydrogen peroxide to maintain a low vaginal pH (3.8–4.5), thereby inhibiting the overgrowth of anaerobic and pathogenic bacteria. Clinical trials are currently evaluating its safety and efficacy in postmenopausal atrophic vaginitis, a condition characterized by vaginal flora imbalance due to decreased estrogen levels.
- Brand names
- Yan Shuo延舒
- Other names
- 阴道用乳杆菌四联活菌胶囊Yindao Yong Ruganjun Silian Huojun Jiaonang
02
Targets
BVAB (Bacterial vaginosis-associated bacteria)
Beyond the preview
Go deeper on live quadruple lactobacillus vaginal capsule.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on live quadruple lactobacillus vaginal capsule.